Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

Respiratory syncytial virus (RSV) is a major cause of virus-induced respiratory disease and hospitalization in infants. Palivizumab, an RSV-neutralizing monoclonal antibody, is used clinically to prevent serious RSV-related respiratory disease in high-risk infants. Motavizumab, an affinity-optimized...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Huang, Kelly, Incognito, Len, Cheng, Xing, Ulbrandt, Nancy D., Wu, Herren
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology (ASM) 2010
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2916538/
https://ncbi.nlm.nih.gov/pubmed/20519399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02699-09
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky